Comparison of Dopamine and Norepinephrine in the treatment of shock after cardiovascular surgery

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CRIS

Registry ID

KCT0002538

Enrollment

420

Registered

2017-11-17

Start date

2017-06-27

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : participant will be randomly assigned to one of the arms (dopamine arm vs norepinephrine arm) if shock occurs by using block randomization table which is supported by Asan Medical Center clinic

s decision. If shock develops again, study drug will be initiated first and then 2nd and 3rd line drugs will be added later as described above.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) adult patients (19-79 years old) who develop shock in the intensive care unit after cardiovascular surgery 2) patients who develop shock once study drugs being infused from the operation room are tapered out under stable vital signs 3) patients who agree to participate the study and sign at informed conset form

Exclusion criteria

Exclusion criteria: 1)patients who have chronic rhythm problems such as chronic supraventricular arrhythmia, or permanent pacemaker insertion or implantable cardiac defibrillators insertion 2) patients who already receive rescue drugs infusion such as epinephrine and vasopressin in the operation room 3) patients who are admitted in the intensive care unit being infused with study drugs from the operating room wtih unstable vital signs 4) patients who develop brain injury as severe as brain death 5) patients who receive mechanical circulatory supports such as intraaortic balloon pump, extracorporeal membrane oxygenation because of refractory shock in the operating room 6)patients who do not develop shock 7) patients who undergo emergency operation 8) patients who already participate other drug related clinical trials

Design outcomes

Primary

Measure	Time frame
arrhythmia (supraventricular and ventricular, sinus tachycardia > 120BPM)	—

Secondary

Measure	Time frame
early mortality with any cause, mortality in the intensive care unit (ICU), hospital stay, ICU stay, early complications	—

Countries

Korea, Republic of

Contacts

Public ContactJu Yong Lim

Asan Medical Center

millalim92@gmail.com+82-2-3010-1777

Outcome results